TRPV4 Inhibition via CD98 Complex Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a specific means to inhibit the mechanical activation of TRPV4, a transmembrane protein implicated in various diseases such as pulmonary edema, inflammation, and hypertension, which is crucial for vascular permeability and drug delivery across barriers.
Innovation Solution
Identification of a domain in CD98 required for the formation of a CD98-TRPV4-β1 integrin complex, allowing for the disruption of this complex to inhibit mechanically-induced TRPV4 activation, using specific polypeptides, nucleic acids, or vectors that target the interaction between TRPV4 and the N-terminus of CD98 or β1 integrin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inhibitors of chemical activation of TRPV4 are used, then chemically-dependent TRPV4 signaling is inhibited, but mechanically-dependent TRPV4 activation remains unaffected
Solution Approach 1:
The patent segments TRPV4 inhibition into two distinct pathways: chemical activation inhibition (using known inhibitors like GSK2193874) and mechanical activation inhibition (using CD98 N-terminus inhibitors). This segmentation allows selective targeting of mechanical activation while preserving chemical activation pathways, achieving specificity for mechanically-dependent diseases.
Solution Approach 2:
The patent identifies CD98 N-terminus as an intermediary component that specifically mediates mechanical activation of TRPV4. By targeting this intermediary rather than TRPV4 directly, the invention achieves selective inhibition of mechanical activation while sparing chemical activation pathways, resolving the contradiction between specificity and versatility.
2Object-affected harmful factors
If TRPV4 is inhibited to treat diseases like pulmonary edema, then vascular permeability is reduced, but drug delivery across barriers may be affected
Solution Approach 1:
The patent enables dynamic control of TRPV4 inhibition by selecting between chemical activation inhibitors, mechanical activation inhibitors, or combinations thereof. This dynamic approach allows clinicians to modulate vascular permeability for disease treatment while preserving drug delivery capabilities when needed, as mechanical and chemical pathways can be independently regulated.
Data Source
AI summary
TRPV4 activation increases vascular permeability and can be triggered by both chemical and mechanical cues. This activation of TRPV4 can contribute to a number of pathological conditions, e.g., edema, inflammation, hypertension, and/or hyperalgesia. Described herein are methods and compositions relating to inhibition of mechanically-induced TRPV4 activation, e.g., for the treatment of pulmonary edema, edema, inflammation, hypertension, and/or hyperalgesia.